Country

United States

Chair

Laurence H. Baker, DO, Chairman, Southwest Oncology Group, 24 Frank Lloyd Wright Drive, PO Box 483, ANN ARBOR, MI 48106, USA. Tel: +1 734 998 7130 Fax: +1 734 998 7118 Emali: bakerl@med.umich.edu

Other Subgroup Head/Member: Deputy Chair

Richard I. Fisher, MD, Deputy Chair, University of Rochester School of Medicine, 601 Elmwood Avenue, PO Box 704, ROCHESTER, NY 14642, USA. Tel: +1 585 275 0842 Fax: +1 585 276 0158 Emali: Richard_Fisher@urmc.rochester.edu

Associate Chair for Cancer Control and Prevention

Charles A. Coltman Jr, MD, Associate Chair for Cancer Control and Prevention, Southwest Oncology Group Operations Office, 14980 Omicron Drive, SAN ANTONIO, TX 78245-3217, USA. Tel: +1 210 450 8808 Fax: +1 210 677 0006 Emali: ccoltman@swog.org

Website

www.swog.org

Title

Docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER-2 positive, stage IV breast cancer.

S0215

Coordinator(s)

Joseph J. Kash, MD, Edward Cancer Center, 120 Spalding Drive, Suite 111, NAPERVILLE, IL 60540-6766, USA. Tel: +1 630 527 3788 Fax: +1 630 527 3790 Email: jkash@lumc.edu

Kathy S. Albain, MD, Loyola University Medical Center, Cancer Center, Bldg 112, Rm 109, 2160 South First Avenue, MAYWOOD, IL 60153-5589, USA. Tel: +1 708 327 3102 Fax: +1 708 327 2210 Email: kalbain@lumc.edu

Summary

Objectives:

• To estimate 1 year survival in HER-2 positive stage IV breast cancer patients using a combination of docetaxel and vinorelbine with concurrent G-CSF support and weekly trastuzumab.
• To estimate the response rate (complete and partial, confirmed and unconfirmed) in the subset of patients with measurable disease.
• To estimate the progression-free survival in patients treated with this regimen.
• To estimate the qualitative and quantitative toxicities of this regimen.
• To obtain tissue blocks for the determination of predictors of response to microtubule interacting agents (such as β-tubulin mutations) and for other future studies.

Scheme

Update

• To date, 51 of the planned 90 patients have been entered. Of 32 currently evaluated for toxicity, 13 (41%) have had grade three and 3 (9.4%) have had grade four toxicities. The latter were confined to neutropenia (2) and anemia (1). No febrile neutropenia or drug-related deaths have occurred to date. The study is expected to reach its accrual objectives within a year.

Related Publications

Slamon D, Clark G, Wong S, et al. Human Breast Cancer: correlation of relapse and survival with amplificaiton of the HER-2/proto-oncogene. Science 1987; 235: 177–82.

Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12.

Norton L, Slamon D, Leyland-Hones B, et al. Overall survival advantage of simultaneous chemotherapy plus the humanized anti-HER-2 monoclonal antibody, herceptin, in HER-2-overexpressing metastatic breast cancer. Proceedings of ASCO 1999; abst 483.

Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER-2 monoclonal antibody (Herceptin) enhances anti-tumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825–31.

Konecny G, Pegram M, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with herceptin against human breast cancer cells with HER-2/neu overexpression. Proceedings of SABCS 1999, abst 467.

Topics

• HER-2 positive patients
• Vinorelbine
• Trastuzumab

Keywords

Docetaxel, vinorelbine tartrate, filgrastim, trastuzumab

***************************************************

Title

Phase III trial of continuous schedule AC + G versus q 2-week schedule AC, followed by paclitaxel given either q 2 weeks or weekly for 12 weeks as post-operative adjuvant therapy in node-positive or high-risk node-negative breast cancer.

S0221

Coordinator(s)

George Thomas Budd, MD, Taussig Cancer Center, R35, Cleveland Clinic Foundation, One Clinic Center, 9500 Euclid Avenue, CLEVELAND, OH 44195-9001, USA. Tel: +1 216 444 6480 Fax: +1 216 445 2360 Email: buddg@ccf.org

Halle C.F. Moore, MD, Cleveland Clinic Foundation, Department of Hematology & Medical Oncology, 9500 Euclid Avenue, CLEVELAND, OH 44195, USA. Tel: +1 216 445 4624 Fax: +1 216 444 9464 Email: mooreh1@ccf.org

Summary

Objectives:

• To compare the disease-free survival of patients with node-positive or high-risk node-negative breast cancer treated with the combination of doxorubicin and cyclophosphamide given q 2 weeks with pegfilgrastim support with that of patients treated with weekly doxorubicin and daily oral cyclophosphamide with filgrastim support, with both treatments to be followed by paclitaxel given according to one of two schedules.
• To compare the disease-free survival of patients with node-positive or high-risk node-negative breast cancer treated with either 12 weeks of weekly paclitaxel or paclitaxel given q 2 weeks with pegfilgrastim support for six cycles following treatment with one of the two doxorubicin/cyclophosphamide regimens discussed above.
• To compare the overall survival produced by the four treatment arms.
• To compare the toxicity of the four treatment arms.
• To examine the association of putative prognostic markers with outcome and the interaction of these markers with treatment.

Scheme

Update

• Accrual on S0221 has been running at about 50 patients per month, with 60% of the registrations coming from SWOG institutions. Although it is the highest-accruing phase III study in SWOG, this rate is only about 30% of that which had been projected. Measures to improve accrual include the commitment of NCI-Canada to join the study (effective in 2006), and the allowance of entry for HER 2 positive patients (with added trastuzumab as per guidelines of N9831), until the new Intergroup trial for HER 2 positive patients is ready to open. In addition, the statistical design has been revised, and the total number required for entry will now be about 3000 rather than 4500, which should permit completion of the study within 5 years of its inception. Available information from a comparison of acute toxicities indicates that the q 2-week “AC” arm, with pegfilgrastim support, is associated with more grade 4 neutropenia than the “metronomic” arm with filgrastim (GCSF) support: 25% versus 6.8%, while hand-foot syndrome of grade 3 is less common on the q 2-week “AC” arm: 1.8% versus 12.4%. Mucositis of grade 3 is less common on the “AC” arms (6.7% versus 18%). One treatment-related death has been reported on each arm.

Related Publications

Henderson I, Berry D, Demetri G, et al. Improved disease-free (dfs) and overall survival (os) from the addition of sequential paclitaxel (t) but not from the escalation of doxorubicin (a) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (bc). Proceedings of ASCO 1998; abst A390A.

Fisher B, Anderson S, Wickerham D, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15(5): 1858–69.

Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclpphosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project -25. J Clin Oncol 1999; 17(11); 3374–88.

Engelsman E, Klijn J, Rubens R, et al. “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: an EORTC breast cancer cooperative group phase III trial (10808). Eur J Cancer 1991; 27(8): 966–70.

Topics

• Node-negative breast cancer
• Node-positive breast cancer

Keywords

Cyclophosphamide, doxorubicin, filgrastim, pegfilgrastim, paclitaxel, trimethoprim sulphate

***************************************************

Title

Phase III randomized trial of anastrozole versus anastrozole and fulves-trant as first line therapy for postmenopausal women with metastatic breast cancer.

S0226

Coordinator(s)

Rita S. Mehta, MD, University of California at Irvine, Chao Family Comprehensive Cancer Center, 101 The City Drive, ORANGE, CA, 92868, USA. Tel: +1 714 456 5153 Fax: +1 714 456 3810 Email: rsmehta@uci.edu

Kathy S. Albain, MD, Loyola University Medical Center, Cancer Center, Bldg 112, Rm 109, 2160 South First Avenue, MAYWOOD, IL 60143-5589, USA. Tel: +1 708 327 3102 Fax: +1 708 327 2210 Email: kalbain@lumc.edu

Summary

Objectives:

• To compare time to tumor progression in postmenopausal women with metastatic breast cancer treated with anastrozole versus anastrozole and fulvestrant.
• To compare clinical benefit (CR, PR, confirmed or unconfirmed, or stable disease ≥24 weeks) and overall survival for this cohort of patients.
• To assess the adverse events of anastrozole as compared to anastro-zole and fulvestrant in this cohort of patients.
• To assess the prognostic significance of subtypes of ER positivity and HER-2 status.
• To assess parameters of estrogen and clinical pharmacology and estrogen levels.
• To compare the anastrozole plasma levels on each treatment arm at 8, 16 and 24 weeks after randomization.
• To compare the estradiol serum levels on each treatment arm at baseline, 8, 16 and 24 weeks after randomization.

Scheme

Update

• This study has underaccrued. A major reason for this is likely to be the requirement, initially built into the trial, that the first 100 patients entered had to undergo serial blood sampling for pharmacokinetic analysis of anastrozole plasma levels: that requirement has been dropped by amendment, after discussion with the pharmaceutical sponsors. A second measure which should substantially improve accrual is the participation by NCI-Canada on this trial nationwide, which is expected to take place in 2006. The study was recently discussed at the SWOG Data Safety and Monitoring Committee, and it was the recommendation of the Committee to continue accrual to the study, based on these considerations.

Related Publications

Klijn J. Blamey R, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19(2): 343–53.

Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19(10): 2596–606.

Osborne C, Coronado-Heinsohn E, Hilsenbeck S, et al. Comparison of effects of a pure steroidal antiestrogen with those of ttamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87(10): 746–50.

Howell A, Robertson J, Aschermannova A, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20(16): 3396–403.

Osborne C, Pippen J, Jones S, et al. Double-Blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with adjuvant breast cancer progressing on prior endocrine therapy: Results of a North American Trial. J Clin Oncol 2002; 20(16): 3386–95.

Topics

• Postmenopausal patients
• Metastatic breast cancer
• Prognostic factors

Keywords

Anastrozole, fulvestrant, surgery

***************************************************

Title

Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer.

S0230

Coordinator(s)

Halle C.F. Moore, MD, Cleveland Clinic Foundation, Department of Hematology & Medical Oncology, 9500 Euclid Avenue, CLEVELAND, OH 44195, USA. Tel: +1 216 445 4624 Fax: +1 216 444 9464 Email: mooreh1@ccf.org

Kathy S. Albain, MD, Loyola University Medical Center, Cancer Center, Bldg 112, Rm 109, 2160 South First Avenue, MAYWOOD, IL 60153-5589, USA. Tel: +1 708 327 3102 Fax: +1 708 327 2210 Email: kalbain@lumc.edu

Summary

Objectives:

• The primary objective of this study is to compare the rate of premature ovarian failure at 2 years following standard adjuvant or neoadjuvant chemotherapy with or without the addition of ovarian suppression with a LHRH analog during chemotherapy in premenopausal women with early stage, hormone-receptor negative breast cancer.
• The secondary objectives are to compare rates of ovarian dysfunction at 1 and 2 years following standard adjuvant or neoadjuvant chemotherapy with or without ovarian suppression and to evaluate ovarian reserve in the two groups at 1 and 2 years. In addition, this study will describe pregnancy and other fertility information in the two groups after treatment and during the 5-year follow-up period.

Scheme

Update

• This trial has suffered to date from underaccrual, raising concern about whether it can continue to successful completion. Efforts to address this problem focused first on other members of the Intergroup, with participation now by CALGB and ECOG. More recently, the European IBCSG has agreed to join the trial. Given the differences in patterns of practice between the US and Europe, it is hoped that participation by the Europeans will boost accrual substantially.

Related Publications

Bines J, Oleske D, Cobleigh M, et al. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14(5): 1718–29.

Koyama H, Wada T, Nishiwasa Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39: 1403–9.

Glode L, Robinson J, Gould S. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981; 1: 1132–4.

Jordan V, Fritz N, Tormey D. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 1987; 47: 624–30.

Rivkees S, Crawford J. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988; 259: 2123–5.

Topics

• Hormone-receptor negative breast cancer
• Premenopausal patients
• Ovarian suppression

Keywords

Goserelin acetate, surgery

***************************************************

Title

Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.

S0307

Coordinator(s)

Julie R. Gralow, MD, Seattle Cancer Care Alliance, 825 Eastlake Ave. E. MS G3-200, SEATTLE, WA 98109-1023, USA. Tel: +1 206 288 7722 Fax: +1 206 288 2054 Email: pink@u.washington.edu

Robert B. Livingston, MD, Seattle Cancer Care Alliance, 825 Eastlake Ave. E. MS G3-200, SEATTLE, WA 98109-1023, USA. Tel: +1 206 288 1085 Fax: +1 206 288 2054 Email: living@u.washington.edu

Summary

Objectives:

• To compare disease-free survival in patients receiving clodronate versus ibandronate versus zoledronic acid as adjuvant therapy for breast cancer.
• To compare overall survival in patients receiving clodronate versus ibandronate versus zoledronic acid as adjuvant therapy for breast cancer.
• To compare the distributions of sites of first recurrence on the three arms.
• To assess the adverse events of clodronate compared to ibandronate compared to zoledronic acid in this cohort of patients.
• To assess the association of PTHrP status and serum N-telopeptide levels at baseline with disease-free survival and sites of first recurrence.
• To test treatment-PTHrP and serum N-telopeptide levels interactions with respect to disease-free survival and sites of first recurrence.

Scheme

Patients will be followed for disease-free and overall survival, as well as sites of first recurrence.

Update

• This study has just been activated. It will involve both the entire Intergroup and the NSABP.

Related Publications

Coleman R, Rubens R. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55(1): 61–6.

Lipton A, Theriault R, Hortobagyi G, et al. Pamidronate prevents skeletal complications and is effective treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000; 88(5): 1082–90.

Paterson A, Powles T, Kanis J, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11(1): 59–65.

van Holten-Verzantvoort A, Kroon H, Bijvoet O, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11(3): 491–8.

Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19(2): 558–67.

Topics

• Bisphosphonates

Keywords

Clodronate, zoledronic acid, ibandronate, bisphosphonate

***************************************************

Title

Phase II trial of simple oral therapy (continuous oral cyclophosphamide and capecitabine) in patients with metastatic breast cancer.

S0430

Coordinator(s)

Anne F. Schott, MD, Southwest Oncology Group, 24 Frank Lloyd Wright Drive, PO Box 483, ANN ARBOR, MI 48106, USA. Tel: +1 734 998 7172 Fax: +1 734 998 7118 Email: aschott@med.umich.edu

Kathy S. Albain, MD, Loyola University Medical Center, Cancer Center, Bldg 112, Rm 109, 2160 South First Avenue, MAYWOOD, IL 60153-5589, USA. Tel: +1 708 327 3102 Fax: +1 708 327 2210 Email: kalbain@lumc.edu

Summary

Objectives:

• To evaluate the response rate (complete and partial, confirmed and unconfirmed) to combination simple oral therapy with cyclophosphamide and capecitabine (CC) in the treatment of metastatic breast cancer in the subset of patients with measurable disease.
• To estimate progression-free survival and overall survival in this population treated with this combination.
• To evaluate the toxicity of this drug combination in metastatic breast cancer.
• To explore the use of MUC-1 antigens (CA 27-29 or CA 15-3) as a surrogate for clinical benefit in patients with non-measurable disease.
• To develop a whole blood and serum repository for patients with metastatic breast cancer for future correlative studies.

Scheme

Update

• To date, 51 of the planned 96 patients had been registered to this study. Six patients are ineligible for the following reasons: four due to disease not satisfying protocol requirements, one due to too many prior chemotherapy regimens, and one due to baseline MUC-1 antigen not within allowed timeframe. Four additional patients that are currently ineligible due to missing baseline data are included in the tables with the eligible patients. Among 13 patients evaluated for toxicity, two experienced Grade 3 lymphopenia.

Related Publications

Lui G, Franssen E, Fitch M, et al. Patient preferences for oval versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15(1): 110–15.

Hainsworth J, Burris H, Erland J, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16(6): 2164–8.

Hainsworth J, Burris H, Yardley D, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearly Cancer Research Network phase II trial. J Clin Oncol 2001; 19(15): 3500–5.

Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4(4): 1013–19.

Toi M, Bando H, Hiriguchi S, et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 2004; 90(12): 2338–43.

Topics

• Capecitabine
• Metastatic breast cancer

Keywords

Capecitabine, cyclophosphamide

***************************************************

Title

A phase II study of goserelin plus anastrozole for the treatment of male patients with hormone-receptor positive metastatic or recurrent breast cancer.

S0511

Coordinator(s)

Zeina Nahleh, MD, University of Cincinnati Medical Center, Barrett Cancer Center, ML 0501, Hematology/Oncology Division, 234 Goodman St., CINCINNATI, OH 45267, USA. Tel: +1 513 584 0223 Fax: +1 513 584 5679 Email: nahlehza@ucmail.uc.edu

Abdur-Rahman Jazieh, MD, MPH, University of Cincinnati Medical Center, Barrett Cancer Center, ML 0501 234 Goodman St., CINCINNATI, OH 45267-0501, USA. Tel: +1 513 584 3830 Fax: +1 513 584 0676 Email: jaziehar@uc.edu

Summary

Objectives:

• To assess progression-free survival (PFS) in male patients with hormone-receptor positive advanced breast cancer treated with the combination of goserelin and anastrozole.
• To assess the overall survival in these patients, and overall objective tumor response rate (confirmed and unconfirmed, complete and partial response) in the subset of these patients with measurable disease.
• To explore the association of prostate specific antigen (PSA), testosterone, estradiol (E2), estrone, estrone sulfate, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and dehydroepiandrosterone (DHEA) levels, with PFS and response.
• To assess toxicity of the drug combination.
• To develop a tissue and serum repository for males with metastatic breast cancer for future correlative studies.

Scheme

Update

• This study has just opened.

Related Publications

Giordano S, Cohen D, Buzdar A, et al. Breast carcinoma in men: a population-based study. Cancer 2004; 101(1): 51–7.

Anderson W, Althuis M, Brinton L, et al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004; 83(1): 77–86.

Giordano S, Buzdar A, Hortobagyi G, et al. Breast cancer in men. Ann Intern Med 2002; 137(8): 678–87.

Goss P, Reid C, Pintilie M, et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer 1998; 85(3): 333–9.

Wang-Rodriguez J, Cross K, Gallagher S, et al. Male breast carcinoma: correlation of ER, PR, Ki-67, HER-2/neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002; 15(8): 853–61.

Topics

• Hormone-receptor positive breast cancer
• Metastatic breast cancer

Keywords

Anastrozole, goserelin acetate, male breast cancer

***************************************************

Title

Randomized placebo-controlled biomarker modulation trial using celecoxib in premenopausal women at high risk for breast cancer. Phase IIb.

S0300

Coordinator(s)

Powel H. Brown, MD, PhD, Baylor College of Medicine, Breast Center, BCM 600, One Baylor Plaza, HOUSTON, TX 77030, USA. Tel: +1 713 798 1609 Fax: +1 713 798 1642 Email: pbrown@breastcenter.tmc.edu

George Thomas Budd, MD, Taussig Cancer Center, R35, Cleveland Clinic Foundation, One Clinic Cneter, 9500 Euclid Avenue, CLEVELAND, OH 44195-9001, USA. Tel: +1 216 444 6480 Fax: +1 216 445 2360 Email: buddg@ccf.org

Julie R. Gralow, MD, Seattle Cancer Care Alliance, 825 Eastlake Ave. E, MS G3-200, SEATTLE, WA 98109-1023, USA. Tel: +1 206 288 7722 Fax: +1 206 288 2054 Email: pink@u.washington.edu

Kathy S. Albain, MD, Loyola University Medical Center, Cancer Center, Bldg 112, Rm 109, 2160 South First Avenue, MAYWOOD, IL 60153-5589, USA. Tel: +1 708 327 3102 Fax: +1 708 327 2210 Email: kalbain@lumc.edu

Allen M. Gown, MD, PhenoPath Laboratories, 551 N 34th Street, Suite 100, SEATTLE, WA 98103-8675, USA. Tel: +1 206 374 9000 Fax: +1 206 374 9009 Email: gown@phenopath.com

Anne McTiernan, MD, PhD, Fred Hutchinson Cancer Research Center, M4-B402, PO Box 19024, SEATTLE, WA 98109, USA. Tel: +1 206 667 7979 Fax: +1 206 667 7850 Email: amctiem@fhcrc.org

Summary

Objectives:

• To assess whether mammographic density is reduced in women at high risk of breast cancer taking celecoxib as compared to high-risk woman taking placebo after 1 year of treatment.
• To assess whether proliferation as measured by Ki67 staining of breast epithelial cells is reduced in women at high risk of breast cancer taking celecoxib as compared to high-risk woman taking placebo after 1 year of treatment.
• To explore the difference in the expression of other biomarkers in breast tissue obtained from women treated with celecoxib as compared to tissue obtained from women treated with placebo. Additional biomarkers to be examined include the COX-2 enzyme and a marker of apoptosis in breast tissue.
• To assess whether IGF-1, IGFBP-3, and PGE2 plasma levels are altered in women at high risk of breast cancer taking celecoxib as compare to woman taking placebo after 1 year of treatment.
• To collect and bank serum and plasma from women at high risk of breast cancer prior to and after treatment with celecoxib for future biomarker analysis.
• To assess the toxicity of celecoxib compared to placebo in this setting.

Scheme

Update

• This study has recently opened.

Related Publications

Fisher B, Constantino J, Wickerham D, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90(18): 1371–88.

Lippman S, Brown P. Tamoxifen precention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst 1999; 91(21): 1809–19.

Osborne C. Tomoxifen in the treatment of breast cancer. N Engl J Med 1998; 339(22): 1609–18.

Pollard M, Luckert P. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980; 64: 1323–7.

Reddy B, Rao C, Rivenson A, et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14(8): 1493–7.

Topics

• Celecoxib
• Premenopausal patients

Keywords

Celecoxib, cancer control